Background and Objectives To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease (AD) risk factors, primary pathology, and neurodegeneration markers. Methods This cross-sectional study was performed in the Alzheimer’s and Families (ALFA+) cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and growth-associated protein-43 (GAP-43) were measured with immunoassays, and synaptosomal-associated protein-25 (SNAP-25) and synaptotagmin-1 were measured with immunoprecipitation mass spectrometry. AD CSF biomarkers β-amyloid (Aβ)42/40, phosphorylated tau (p-tau), and total tau and the neurodegeneration biomarker neurofilam...
It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic function ...
OBJECTIVE: In Alzheimer disease (AD), longitudinal changes of beta-amyloid1-42 (Aβ1-42), tau, and ph...
Abstract Background There is accumulating evidence that synaptic loss precedes neuronal loss and cor...
Background and Objectives To determine whether CSF synaptic biomarkers are altered in the early prec...
Objective: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage o...
Background and objectives: To determine whether CSF synaptic biomarkers are altered in the early pre...
AIMS: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especia...
Objective To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroi...
Background: We investigated whether a panel of 12 potential novel biomarkers consisting of proteins ...
Introduction We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, an...
Background: Understanding the changes that occur in the transitional stage between absent and overt ...
Biomarkers for Alzheimer’s disease (AD) is a growing field of research. A particularly vibrant field...
BACKGROUND AND OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers amyloid-β42 (Aβ42), phosphorylated t...
OBJECTIVE: To assess the ability of a combination of synaptic CSF biomarkers to separate AD and non-...
Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mecha...
It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic function ...
OBJECTIVE: In Alzheimer disease (AD), longitudinal changes of beta-amyloid1-42 (Aβ1-42), tau, and ph...
Abstract Background There is accumulating evidence that synaptic loss precedes neuronal loss and cor...
Background and Objectives To determine whether CSF synaptic biomarkers are altered in the early prec...
Objective: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage o...
Background and objectives: To determine whether CSF synaptic biomarkers are altered in the early pre...
AIMS: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especia...
Objective To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroi...
Background: We investigated whether a panel of 12 potential novel biomarkers consisting of proteins ...
Introduction We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, an...
Background: Understanding the changes that occur in the transitional stage between absent and overt ...
Biomarkers for Alzheimer’s disease (AD) is a growing field of research. A particularly vibrant field...
BACKGROUND AND OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers amyloid-β42 (Aβ42), phosphorylated t...
OBJECTIVE: To assess the ability of a combination of synaptic CSF biomarkers to separate AD and non-...
Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mecha...
It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic function ...
OBJECTIVE: In Alzheimer disease (AD), longitudinal changes of beta-amyloid1-42 (Aβ1-42), tau, and ph...
Abstract Background There is accumulating evidence that synaptic loss precedes neuronal loss and cor...